Abundance Wealth Counselors reduced its stake in GSK plc (NYSE:GSK – Free Report) by 6.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 21,011 shares of the pharmaceutical company’s stock after selling 1,404 shares during the quarter. Abundance Wealth Counselors’ holdings in GSK were worth $711,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Eastern Bank acquired a new position in shares of GSK in the third quarter valued at approximately $26,000. Sunbelt Securities Inc. increased its position in GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares during the period. Crews Bank & Trust bought a new stake in shares of GSK during the 4th quarter worth approximately $26,000. Concord Wealth Partners raised its holdings in shares of GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after buying an additional 547 shares in the last quarter. Finally, ST Germain D J Co. Inc. grew its holdings in shares of GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 522 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.
GSK Stock Performance
Shares of GSK stock opened at $35.20 on Friday. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.92. The firm has a 50 day moving average of $34.07 and a 200-day moving average of $37.69. The company has a market cap of $72.96 billion, a price-to-earnings ratio of 22.86, a price-to-earnings-growth ratio of 1.37 and a beta of 0.63.
Wall Street Analyst Weigh In
Read Our Latest Analysis on GSK
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Featured Stories
- Five stocks we like better than GSK
- Using the MarketBeat Dividend Yield Calculator
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- How to Start Investing in Real Estate
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- What is the Dogs of the Dow Strategy? Overview and Examples
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSK – Free Report).
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.